Danielle Brander, MD

Dr. Brander asks about synthesizing comparative analyses and important limitations clinicians should understand when interpreting cross-trial comparisons, including balancing insights with other evidence forms.

Dr. Brander introduces the third analysis comparing zanubrutinib from SEQUOIA with acalabrutinib plus venetoclax from AMPLIFY, representing an anchored analysis with similar comparison arms showing zanubrutinib association with prolonged progression-free survival when adjusting for baseline characteristics.

Dr. Shadman transitions to discussing the second analysis comparing zanubrutinib as continuous therapy versus venetoclax-obinutuzumab fixed-duration regimen, the previously preferred approved fixed-duration option in the United States.

Dr. Brander discusses the comparison of zanubrutinib from the SEQUOIA trial with fixed-duration venetoclax plus ibrutinib from GLOW and CAPTIVATE studies, examining patient populations and study design relevance.

Dr. Mazyar Shadman from the University of Washington and Fred Hutchinson Cancer Center and Dr. Danielle Brander from Duke Cancer Institute introduce their discussion on interpreting matching adjusted indirect comparisons (MIACs) to inform first-line chronic lymphocytic leukemia (CLL) treatment decisions. The focus centers on how recent comparative analyses help clinicians choose between continuous BTK inhibitor therapy versus fixed-duration venetoclax-based therapies in clinical practice.

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.